Characterization of hepatitis B virus genotypes and quantitative hepatitis B surface antigen titres in North American tertiary referral liver centres

Liver International

Volumn 33, Issue 9, 2013, Pages 1363-1369

  Congly, Stephen E ^a   Wong, Philip ^b   Al Busafi, Said A ^b   Doucette, Karen ^c   Fung, Scott K ^d   Ghali, Peter ^b   Fonseca, Kevin ^e   Myers, Robert P ^a   Osiowy, Carla ^f   Coffin, Carla S ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

^f PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

Canada; Chronic hepatitis B; HBV DNA; HBV genotype; Quantitative hepatitis B surface antigen

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIAN; CAUCASIAN; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER BIOPSY; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PATIENT REFERRAL; POLYMERASE CHAIN REACTION; SEROLOGY; VERTICAL TRANSMISSION; VIRUS CHARACTERIZATION;

CANADA; CHRONIC HEPATITIS B; HBV DNA; HBV GENOTYPE; QUANTITATIVE HEPATITIS B SURFACE ANTIGEN;

ADULT; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; CANADA; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84883753119     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12222     Document Type: Article

References (47)

1. Okamoto H, Tsuda F, Sakugawa H, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988; 69: 2575-83.
2. Norder H, Hammas B, Löfdahl S, Couroucé AM, Magnius LO. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J Gen Virol 1992; 73: 1201-8.
3. Ohba K, Mizokami M, Ohno T, et al. Relationships between serotypes and genotypes of hepatitis B virus: genetic classification of HBV by use of surface genes. Virus Res 1995; 39: 25-34.
4. Cooksley WGE. Do we need to determine viral genotype in treating chronic hepatitis B? J Viral Hepat 2010; 17: 601-10.
5. Lin C-L, Kao J-H. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011; 26(Suppl. 1): 123-30.
6. Schaefer S. Hepatitis B virus: significance of genotypes. J Viral Hepat 2005; 12: 111-24.
7. Chu C-J, Hussain M, Lok ASF. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122: 1756-62.
8. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-9.
9. Yu M-W, Yeh S-H, Chen P-J, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97: 265-72.
10. Toan NL, Song LH, Kremsner PG, et al. Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. Hepatology 2006; 43: 1375-84.
11. Buster EHCJ, Hansen BE, Lau GKK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-9.
12. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123: 1848-56.
13. Chu C-J, Keeffe EB, Han S-H, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38: 619-28.
14. Westland C, Delaney W 4th, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003; 125: 107-16.
15. Gaglio P, Singh S, Degertekin B, et al. Impact of the hepatitis B virus genotype on pre- and post-liver transplantation outcomes. Liver Transpl 2008; 14: 1420-7.
16. Panessa C, Hill WD, Giles E, et al. Genotype D amongst injection drug users with acute hepatitis B virus infection in British Columbia. J Viral Hepat 2009; 16: 64-73.
17. Livingston SE, Simonetti JP, McMahon BJ, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis 2007; 195: 5-11.
18. Zhang J, Zou S, Giulivi A. Epidemiology of hepatitis B in Canada. Can J Infect Dis 2001; 12: 345-50.
19. Rossi C, Shrier I, Marshall L, et al. Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis. PLoS One 2012; 7: e44611.
20. Fung SK, Wong FSH, Wong DKH, Hussain MT, Lok ASF. Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center. Liver Int 2006; 26: 796-804.
21. Osiowy C, Larke B, Giles E. Distinct geographical and demographic distribution of hepatitis B virus genotypes in the Canadian Arctic as revealed through an extensive molecular epidemiological survey. J Viral Hepat 2011; 18: e11-9.
22. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-22.
23. Wursthorn K, Jaroszewicz J, Zacher BJ, et al. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol 2011; 50: 292-6.
24. Sonneveld MJ, Rijckborst V, Boucher CAB, et al. A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. J Clin Virol 2011; 51: 175-8.
25. Seto W-K, Wong DK-H, Fung J, et al. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 2012; 56: 812-9.
26. Coffin CS, Fung SK, Ma MM, Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012; 26: 917-38.
27. Yilmaz Y, Yonal O, Kurt R, et al. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepat Mon 2011; 11: 103-6.
28. Shin WG, Park SH, Jang MK, et al. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis 2008; 40: 267-74.
29. Zhu X, Wang L-C, Chen E-Q, et al. Prospective evaluation of FibroScan for the diagnosis of hepatic fibrosis compared with liver biopsy/AST platelet ratio index and FIB-4 in patients with chronic HBV infection. Dig Dis Sci 2011; 56: 2742-9.
30. Osiowy C, Giles E. Evaluation of the INNO-LiPA HBV genotyping assay for determination of hepatitis B virus genotype. J Clin Microbiol 2003; 41: 5473-7.
31. Zacher BJ, Moriconi F, Bowden S, et al. Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. Clin Vaccine Immunol 2011; 18: 1943-50.
32. Maylin S, Boyd A, Delaugerre C, et al. Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus. Clin Vaccine Immunol 2012; 19: 242-8.
33. Nguyen T, Thompson AJV, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508-13.
34. Rodriguez-Frias F, Jardi R, Buti M, et al. Hepatitis B virus genotypes and G1896A precore mutation in 486 Spanish patients with acute and chronic HBV infection. J Viral Hepat 2006; 13: 343-50.
35. Teshale EH, Ramachandran S, Xia G-L, et al. Genotypic distribution of hepatitis B virus (HBV) among acute cases of HBV infection, selected United States counties, 1999-2005. Clin Infect Dis 2011; 53: 751-6.
36. Statistics Canada. Census of Population, Statistics Canada catalogue no. 97-562-XCB2006006 (British Columbia/Colombie-Britannique, Code59). 2006.
37. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CAB, Janssen HLA. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011; 204: 415-8.
38. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52: 1611-20.
39. Reijnders JGP, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449-54.
40. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
41. Peng C-Y, Lai H-C, Li Y-F, et al. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2012; 35: 458-68.
42. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-61.
43. Zhou B, Liu M, Lv G, et al. Quantification of hepatitis B surface antigen and E antigen: correlation between Elecsys and Architect assays. J Viral Hepat 2013; 20: 422-9.
44. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a. Antivir Ther (Lond) 2009; 14: 1183-8.
45. Togo S, Arai M, Tawada A, et al. Clinical importance of serum hepatitis B surface antigen levels in chronic hepatitis B. J Viral Hepat 2011; 18: e508-15.
46. Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients. J Hepatol 2013; 58: 1089-95.
47. McNabb A, Chen R, McNabb G, Krajden M, Isaac Renton J. Prevalence of genotype and lamivudine resistance in hepatitis B viruses in British Columbia from 2000 to 2005. Can J Infect Dis Med Microbiol 2006; 17: 74.